Related projects
Discover more projects across a range of sectors and discipline — from AI to cleantech to social innovation.
Ibrutinib has proven to be very effective in newly diagnosed and relapsed chronic lymphocytic leukemia (CLL) patients. However, it can cause certain side effects that can lead to early discontinuation of treatment and worse outcomes for patients. The goal of this study is to determine the frequency of side effects in the “real-world” associated with ibrutinib compared to standard therapy using provincial administrative data. We further aim to assess the impact of ibrutinib dose interruptions and reductions on survival outcomes, as well as the impact and cost of the side effects of therapy on the public health care system. As a subproject, we aim to determine survival outcomes of patients based on predictive markers analyzed at diagnosis and at time of treatment. Results from our study will provide information to health care organizations regarding “real-world” risks of ibrutinib and the value of predictive markers to the health of CLL patients.
Alina Gerrie
Rania Khelifi
Vancouver General Hospital
Medicine
Health care and social assistance
University of British Columbia
Accelerate
Discover more projects across a range of sectors and discipline — from AI to cleantech to social innovation.
Find the perfect opportunity to put your academic skills and knowledge into practice!
Find ProjectsThe strong support from governments across Canada, international partners, universities, colleges, companies, and community organizations has enabled Mitacs to focus on the core idea that talent and partnerships power innovation — and innovation creates a better future.